Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RIGL Stock Forecast 2026-2027
$41.67
Current Price
$750.07M
Market Cap
Buy 3
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RIGL Price Targets
+94.4%
To High Target of $81.00
+20.0%
To Median Target of $50.00
-4.0%
To Low Target of $40.00
RIGL Price Momentum
-2.1%
1 Week Change
+24.9%
1 Month Change
+120.4%
1 Year Change
-2.7%
Year-to-Date Change
-20.2%
From 52W High of $52.24
+123.3%
From 52W Low of $18.66
📊 TOP ANALYST CALLS
Did RIGL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Rigel is one of their latest high-conviction picks.
Latest RIGL Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, RIGL has a bullish consensus with a median price target of $50.00 (ranging from $40.00 to $81.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $41.67, the median forecast implies a 20.0% upside. This outlook is supported by 3 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RIGL Analyst Ratings
3
Buy
2
Hold
0
Sell
RIGL Price Target Range
Low
$40.00
Average
$50.00
High
$81.00
Current: $41.67
Latest RIGL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RIGL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 2, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| May 27, 2026 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $57.00 |
| May 22, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 13, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 7, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Nov 5, 2025 | Jefferies | Buy | Upgrade | $N/A | |
| Nov 5, 2025 | Cantor Fitzgerald | Neutral | Maintains | $N/A | |
| Oct 8, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 6, 2025 | Cantor Fitzgerald | Neutral | Maintains | $N/A | |
| May 7, 2025 | Cantor Fitzgerald | Neutral | Maintains | $N/A | |
| Mar 6, 2025 | Citigroup | Buy | Maintains | $N/A | |
| Mar 5, 2025 | B. Riley Securities | Neutral | Maintains | $N/A | |
| Mar 5, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 23, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 22, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 10, 2024 | Cantor Fitzgerald | Neutral | Maintains | $N/A | |
| Dec 10, 2024 | B. Riley Securities | Neutral | Maintains | $N/A | |
| Dec 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 6, 2024 | B. Riley Securities | Neutral | Maintains | $N/A |
Rigel Pharmaceuticals, Inc. (RIGL) Competitors
The following stocks are similar to Rigel based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rigel Pharmaceuticals, Inc. (RIGL) Financial Data
Rigel Pharmaceuticals, Inc. has a market capitalization of $750.07M with a P/E ratio of 2.2x. The company generates $299.77M in trailing twelve-month revenue with a 121.5% profit margin.
Revenue growth is +10.3% quarter-over-quarter, while maintaining an operating margin of +20.2% and return on equity of +174.1%.
Valuation Metrics
Market Cap
$750.07M
Enterprise Value
$670.02M
P/E Ratio
2.2x
PEG Ratio
-0.1x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
+10.3%
Gross Margin
+92.2%
Operating Margin
+20.2%
Net Margin
+121.5%
EPS Growth
-24.4%
Financial Health
Cash/Price Ratio
+19.0%
Current Ratio
2.6x
Debt/Equity
11.4x
ROE
+174.1%
ROA
+22.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Rigel Pharmaceuticals, Inc. (RIGL) Business Model
About Rigel Pharmaceuticals, Inc.
What They Do
Biotechnology company developing therapies for cancer and hematologic disorders.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, generating revenue primarily through the development and commercialization of targeted drugs for hematologic and oncological conditions. Rigel Pharmaceuticals focuses on advancing its drug candidates through clinical trials and partnerships, which can lead to licensing agreements and potential royalties upon product commercialization.
Additional Information
Founded in 1996 and headquartered in South San Francisco, California, Rigel Pharmaceuticals emphasizes innovation in precision medicine. Its research pipeline includes IRAK1/4 and RIPK1 inhibitors, addressing significant unmet medical needs in specialized biopharma markets. The company actively engages in clinical trials and expanded access policies to ensure its therapies reach patients effectively.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
162
CEO
Mr. Raul R. Rodriguez
Country
United States
IPO Year
2000
Website
www.rigel.comRigel Pharmaceuticals, Inc. (RIGL) Latest News & Analysis
Latest News
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10 days ago
Quick Summary
Rigel Pharmaceuticals granted awards under its Inducement Plan to attract new employees, as approved by its Board, in line with NASDAQ regulations.
Why It Matters
Rigel Pharmaceuticals' employee inducement awards may signal growth and recruitment efforts, indicating confidence in future performance, which can influence stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rigel Pharmaceuticals announced Dr. Hannah's resignation from its Board to join the company, with Alison L. appointed to the Board effective July 1, 2026.
Why It Matters
Dr. Hannah's resignation could signal changes in Rigel's strategic direction or leadership dynamics, impacting investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rigel Pharmaceuticals, with a market cap over $600M, saw a 35% pullback. Q1 revenues rose 10% to $58.8M, with net product revenues up 26%. FY2026 sales guidance remains $275–$290M.
Why It Matters
Rigel Pharmaceuticals offers a compelling investment opportunity with a strong growth strategy, rising revenues, and maintained sales guidance, despite recent stock pullback.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Rigel Pharmaceuticals has closed a license agreement for VEPPANUTM (vepdegestrant) after meeting regulatory requirements, potentially impacting its operations in hematologic disorders and cancer.
Why It Matters
Rigel Pharmaceuticals' license agreement for VEPPANUTM signals potential growth in its product pipeline, impacting future revenue and market position in the biotech sector.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rigel Pharmaceuticals (Nasdaq: RIGL) CEO Raul Rodriguez will present at the Jefferies Global Healthcare Conference on June 3, 2026, at 8:45 a.m.
Why It Matters
Rigel Pharmaceuticals' CEO presentation at a major healthcare conference could signal potential developments in their pipeline, impacting stock performance and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
1 month ago
Quick Summary
Rigel Pharmaceuticals will present final data from the Phase 3 AcceleRET-Lung trial for GAVRETO® as a first-line treatment for RET fusion-positive NSCLC at the ASCO Annual Meeting on May 29, 2026.
Why It Matters
The presentation of Phase 3 trial data for GAVRETO® could impact Rigel Pharmaceuticals' stock value, indicating potential market approval and future revenue from lung cancer treatments.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RIGL Stock
What is Rigel Pharmaceuticals, Inc.'s (RIGL) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Rigel Pharmaceuticals, Inc. (RIGL) has a median price target of $50.00. The highest price target is $81.00 and the lowest is $40.00.
Is RIGL stock a good investment in 2027?
According to current analyst ratings, RIGL has 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $41.67. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RIGL stock?
Wall Street analysts predict RIGL stock could reach $50.00 in the next 12 months. This represents a 20.0% increase from the current price of $41.67. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rigel Pharmaceuticals, Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, generating revenue primarily through the development and commercialization of targeted drugs for hematologic and oncological conditions. Rigel Pharmaceuticals focuses on advancing its drug candidates through clinical trials and partnerships, which can lead to licensing agreements and potential royalties upon product commercialization.
What is the highest forecasted price for RIGL Rigel Pharmaceuticals, Inc.?
The highest price target for RIGL is $81.00 from at , which represents a 94.4% increase from the current price of $41.67.
What is the lowest forecasted price for RIGL Rigel Pharmaceuticals, Inc.?
The lowest price target for RIGL is $40.00 from at , which represents a -4.0% decrease from the current price of $41.67.
What is the overall RIGL consensus from analysts for Rigel Pharmaceuticals, Inc.?
The overall analyst consensus for RIGL is bullish. Out of 4 Wall Street analysts, 3 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $50.00.
How accurate are RIGL stock price projections?
Stock price projections, including those for Rigel Pharmaceuticals, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 17, 2026 10:41 PM UTC